Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

BIOCRYST PF Form 4 May 25, 2016	IARMACEUT	FICALS I	NC								
FORM A								-	OMB APPROVAL		
-	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235-0287		
Check this b if no longer subject to Section 16. Form 4 or	STATEN	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type Resp	ponses)										
1. Name and Address of Reporting Person <u>*</u> INGRAM ROBERT ALEXANDER							Issuer	tionship of Reporting Person(s) to			
		INC [E		IARMAC	EUTICAI	LS (Cheo	(Check all applicable)				
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year)			X Director Officer (give	e title Oth	% Owner her (specify			
280 S. MANG 350	below) below)										
	4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(CheckApplicable Line)_X_ Form filed by One Reporting Person							
DURHAM, NO	C 27701						Form filed by M Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	ole I - Non-	-Derivative	Securities A	Acquired, Disposed o	of, or Beneficia	lly Owned		
	Fransaction Date onth/Day/Year)		Date, if	3. Transacti Code (Instr. 8)	4. Securi onAcquired Disposed (Instr. 3,	(A) or of (D) 4 and 5) (A)	Securities I Beneficially (Owned (6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	or (D) Price	(Instr. 3 and 4)				
Reminder: Report	on a separate line	e for each cl	ass of sec	urities ben	eficially ow	ned directly	or indirectly.				
					inforı requi	mation con red to resp ays a curre	spond to the collect tained in this form bond unless the for ently valid OMB cor	are not m	SEC 1474 (9-02)		
	Tab					sposed of, or convertible	r Beneficially Owned securities)				

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amoun
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securiti

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amou or Numl of Sh
Automatic Stock Option Grant (1)	\$ 3.22	05/23/2016		А	30,000	06/23/2016 <u>(2)</u>	05/23/2026	Common Stock	30,0

Reporting Owners

Reporting Owner Name / Address	Relationships						
FB	Director	10% Owner	Officer	Other			
INGRAM ROBERT ALEXANDER 280 S. MANGUM STREET SUITE 350 DURHAM, NC 27701	Х						
Signatures							
/s/ Alane P. Barnes, by power of attorney		05/25/2016					
<u>**</u> Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
- (2) Vests 1/12th per month over twelve months beginning June 23, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.